Frankfurt, Hesse, Germany
Senior Biopharma and Biotechnology leader with over 20years of early and late stage drug development experience across multiple therapeutic areas. Executive Director Biopharma R&D. Experienced in leading large global development teams with diverse skill sets and cultural background as a line manager (>70) and in matrix organizations. In depth knowledge in US, EU, APAC biopharma and biotech landscape and region specific precision medicine approaches and healthcare systems. Proven track record in translational medicine with respect to implementing highly innovative & efficient approaches for drug development and patient stratification. Helping to improve patients lives means a lot to me. Specialties: Strategic Innovation, Precision Medicine, Translational Medicine, Biomarkers & CDx, Advanced Data Analytics including AI/ML applications, Oncology, Immuno-Oncology, Immunology, Neurology, Anti-infectives, advanced data analytics, management/ change management, external/ open innovation, (lean) business process set up and implementation, US, Israelian and GER biotech industry (business analyses; start up incubators) #healthcareinnovation
Executive Director Driving & enabling strategic innovation along the R&D continuum, in collaboration with R&D stakeholders/ customers, together with external innovation & business development, MVentures and across Merck group divisions. Focus on data science, AI/ML-powered drug development, biomarker & companion diagnostics, quantitative pharmacology, epidemiology, biostatistics and strategy & operations. Emphasis on collaboration, ideation, value creation and implementation/ impact.
- May 2020 Executive Director Clinical Biomarkers & CDx, Translational Medicine - Feb 2016 Senior Director Clinical Biomarkers & Companion Diagnostics - Nov 2014 Director Clinical Biomarkers - Precision medicine lead (crossfunctional Merck Biopharma initiative) - Head of a global biomarker & CDx organization - Development of innovative and efficient clinical biomarker strategies - Development of clinical biomarker strategies for immuno-oncology & oncology programs - Translate scientific concepts into smart & robust clinical development strategies - Application of cutting edge technologies for biomarker-based hypothesis generations in clinical development & early assessment of market enabling Technologies - Merck VFA delegate for personalized medicine (Association of Research-Based Pharmaceutical Companies, Berlin/Germany)
- Integrated exloratory medicine concepts - Representing clinical pharmacology in global program teams - Global early development leader of 2 clinical oncology programs (phase I-II) - Design and scientific supervision of clinical pharmacology trials
Global Head Clinical Biomarkers & Companion Diagnostics Senior Director Same position as I held when I was located in Darmstadt, GER
Bayer Anti-Infectives Spin-out. Active contribution to successful outlicensing of a HCMV program (End of phase II) Responsible for various programs HIV, HBV, Antibacterials Responsible for the conduct and planning of various investigations (e.g. PK/PD, POPPK, etc.)
Contribution to the marketing authorization of Veregen in Europe Responsible for a Phase II program with successful PoC in pancreatic cancer Responsible for a Phase II program for the treatment of autoimmune diseases Functional representation of the project team during scientific advices and out-licensing activities Scientific publication of Phase II results (oncology) Leading a team of 7 scientists Change management Involved in re-structuring of a R&D Organization of approx. 200FTE
Drug development services for pharma and biotech companies Study Director for in vitro ADME and Tox-Studies Deputy-Head of a GLP certified test facility Responsible for the set-up and maintenance of a quality assurance system (GLP categories 3 and 9) Responsible person for biological safety Leading a team of 10-15 scientists and technicians